Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Podcast: Drug Price Negotiations, Kids COVID Vaccine Deployed, FDA Chief Scientist Leaves

Executive Summary

Pink Sheet reporters and editors discuss the congressional agreement to allow Medicare drug pricing negotiation, the authorization of the Pfizer/BioNTech vaccine for children age 5 to 11, and the departure of the US FDA’s Chief Scientist.

You may also be interested in...



In Case You Missed It: China’s ‘Dual Circulation’ Policy, Fixing Safety Data ‘Overload,’ And More

We clean out your Thanksgiving inbox so you don't have to.

Pink Sheet Podcast: COVID-19 Boosters For Adults, Aduhelm And Part B, Califf For FDA Commissioner

Pink Sheet reporters and editors discuss the authorization of COVID-19 vaccine booster shots for all adults, Aduhelm’s impact on Medicare Part B and rejection by EMA, and the nomination of ex-FDA commissioner Robert Califf for another term.

Pink Sheet Podcast: Kids’ COVID-19 Vaccines, Merck Shares COVID Pill, Accelerated Approval Problems

Pink Sheet reporters and editors discuss the issues that could arise when the COVID-19 vaccines are given to children age 5 to 11, Merck’s agreement to share the license for its proposed oral COVID-19 treatment, and problems for a sponsor blocked by an accelerated approval conversion to full approval.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel